Literature DB >> 17150213

Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation.

J R Brouwer1, E J Mientjes, C E Bakker, I M Nieuwenhuizen, L A Severijnen, H C Van der Linde, D L Nelson, B A Oostra, R Willemsen.   

Abstract

The human FMR1 gene contains a CGG repeat in its 5' untranslated region. The repeat length in the normal population is polymorphic (5-55 CGG repeats). Lengths beyond 200 CGGs (full mutation) result in the absence of the FMR1 gene product, FMRP, through abnormal methylation and gene silencing. This causes Fragile X syndrome, the most common inherited form of mental retardation. Elderly carriers of the premutation, defined as a repeat length between 55 and 200 CGGs, can develop a progressive neurodegenerative syndrome: Fragile X-associated tremor/ataxia syndrome (FXTAS). In FXTAS, FMR1 mRNA levels are elevated and it has been hypothesised that FXTAS is caused by a pathogenic RNA gain-of-function mechanism. We have developed a knock in mouse model carrying an expanded CGG repeat (98 repeats), which shows repeat instability and displays biochemical, phenotypic and neuropathological characteristics of FXTAS. Here, we report further repeat instability, up to 230 CGGs. An expansion bias was observed, with the largest expansion being 43 CGG units and the largest contraction 80 CGG repeats. In humans, this length would be considered a full mutation and would be expected to result in gene silencing. Mice carrying long repeats ( approximately 230 CGGs) display elevated mRNA levels and decreased FMRP levels, but absence of abnormal methylation, suggesting that modelling the Fragile X full mutation in mice requires additional repeats or other genetic manipulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150213      PMCID: PMC1852528          DOI: 10.1016/j.yexcr.2006.10.002

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  41 in total

1.  Premature ovarian failure among fragile X premutation carriers: parent-of-origin effect?

Authors:  S L Sherman
Journal:  Am J Hum Genet       Date:  2000-06-12       Impact factor: 11.025

2.  Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.

Authors:  A Kenneson; F Zhang; C H Hagedorn; S T Warren
Journal:  Hum Mol Genet       Date:  2001-07-01       Impact factor: 6.150

3.  Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.

Authors:  R J Hagerman; M Leehey; W Heinrichs; F Tassone; R Wilson; J Hills; J Grigsby; B Gage; P J Hagerman
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

4.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

5.  Active demethylation of the paternal genome in the mouse zygote.

Authors:  J Oswald; S Engemann; N Lane; W Mayer; A Olek; R Fundele; W Dean; W Reik; J Walter
Journal:  Curr Biol       Date:  2000-04-20       Impact factor: 10.834

6.  Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  Jim Grigsby; Angela G Brega; Sébastien Jacquemont; Danuta Z Loesch; Maureen A Leehey; Glenn K Goodrich; Randi J Hagerman; Jennifer Epstein; Rebecca Wilson; Jennifer B Cogswell; Tristan Jardini; Flora Tassone; Paul J Hagerman
Journal:  J Neurol Sci       Date:  2006-06-15       Impact factor: 3.181

7.  Instability of a (CGG)98 repeat in the Fmr1 promoter.

Authors:  C J Bontekoe; C E Bakker; I M Nieuwenhuizen; H van der Linde; H Lans; D de Lange; M C Hirst; B A Oostra
Journal:  Hum Mol Genet       Date:  2001-08-01       Impact factor: 6.150

8.  Instability of a premutation-sized CGG repeat in FMR1 YAC transgenic mice.

Authors:  Andrea M Peier; David L Nelson
Journal:  Genomics       Date:  2002-10       Impact factor: 5.736

9.  Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse.

Authors:  C E Bakker; Y de Diego Otero; C Bontekoe; P Raghoe; T Luteijn; A T Hoogeveen; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

10.  Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.

Authors:  Roberta Pietrobono; Maria Grazia Pomponi; Elisabetta Tabolacci; Ben Oostra; Pietro Chiurazzi; Giovanni Neri
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

View more
  72 in total

Review 1.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

2.  FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile.

Authors:  L Santa María; A Pugin; M A Alliende; S Aliaga; B Curotto; T Aravena; H-T Tang; G Mendoza-Morales; R Hagerman; F Tassone
Journal:  Clin Genet       Date:  2013-10-13       Impact factor: 4.438

3.  Mouse models of the fragile x premutation and the fragile X associated tremor/ataxia syndrome.

Authors:  Michael R Hunsaker; Gloria Arque; Robert F Berman; Rob Willemsen; Renate K Hukema
Journal:  Results Probl Cell Differ       Date:  2012

4.  Nucleosomal occupancy and CGG repeat expansion: a comparative analysis of triplet repeat region from mouse and human fragile X mental retardation gene 1.

Authors:  Sonal Datta; Mohammad Parwez Alam; Subeer S Majumdar; Abhishek Kumar Mehta; Souvik Maiti; Neerja Wadhwa; Vani Brahmachari
Journal:  Chromosome Res       Date:  2011-04-16       Impact factor: 5.239

Review 5.  What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Authors:  Molly M Foote; Milo Careaga; Robert F Berman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

6.  iPSC-derived forebrain neurons from FXS individuals show defects in initial neurite outgrowth.

Authors:  Matthew E Doers; Michael T Musser; Robert Nichol; Erich R Berndt; Mei Baker; Timothy M Gomez; Su-Chun Zhang; Leonard Abbeduto; Anita Bhattacharyya
Journal:  Stem Cells Dev       Date:  2014-04-30       Impact factor: 3.272

Review 7.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

8.  Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo.

Authors:  Renate K Hukema; Ronald A M Buijsen; Chris Raske; Lies Anne Severijnen; Ingeborg Nieuwenhuizen-Bakker; Michelle Minneboo; Alex Maas; Rini de Crom; Johan M Kros; Paul J Hagerman; Robert F Berman; Rob Willemsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

10.  Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation.

Authors:  H Jürgen Wenzel; Michael R Hunsaker; Claudia M Greco; Rob Willemsen; Robert F Berman
Journal:  Brain Res       Date:  2010-01-04       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.